Alexander I. Mikhalev

Alexander I. Mikhalev

Auto-generated profile, based on publicly available information

Alexander I. Mikhalev

Pirogov Russian National Research Medical University; Academician G.M. Savelyeva City Clinical Hospital No. 31

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Cells
Verified
Journal Article
Open access
PDF file
NSNikolay K Shakhpazyan
Nikolay K Shakhpazyan
LMLiudmila Mikhaleva
Liudmila Mikhaleva
ABArkady Bedzhanyan
Arkady Bedzhanyan
ZGZarina Gioeva
Zarina Gioeva
AMAlexander I. Mikhalev
Alexander I. Mikhalev
ABAndrey E. Biryukov
Andrey E. Biryukov
The gut microbiota plays an essential role in maintaining immune homeostasis and influencing the immune landscape within the tumor microenvironment. This review aims to elucidate the interactions between gut microbiota and tumor immune dynamics, with a focus on colorectal cancer (CRC). The review spans foundational concepts of immuno-microbial interplay, factors influencing microbiome composition, and evidence linking gut microbiota to cancer immunotherapy outcomes. Gut microbiota modulates anti-cancer immunity through several mechanisms, including enhancement of immune surveillance and modulation of inflammatory responses. Specific microbial species and their metabolic byproducts can significantly influence the efficacy of cancer immunotherapies. Furthermore, microbial diversity within the gut microbiota correlates with clinical outcomes in CRC, suggesting potential as a valuable biomarker for predicting response to immunotherapy. Conclusions: Understanding the relationship between gut microbiota and tumor immune responses offers potential for novel therapeutic strategies and biomarker development. The gut microbiota not only influences the natural history and treatment response of CRC but also serves as a critical modulator of immune homeostasis and anti-cancer activity. Further exploration into the microbiome’s role could enhance the effectiveness of existing treatments and guide the development of new therapeutic modalities.

23 August 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
NSNikolay K Shakhpazyan
Nikolay K Shakhpazyan
LMLiudmila Mikhaleva
Liudmila Mikhaleva
ABArkady Bedzhanyan
Arkady Bedzhanyan
ZGZarina Gioeva
Zarina Gioeva
НСНиколай Садыхов
Николай Садыхов
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
Colorectal cancer (CRC) is a major health burden worldwide and is the third most common type of cancer. The early detection and diagnosis of CRC is critical to improve patient outcomes. This review explores the intricate interplay between the tumor microenvironment, stromal interactions, and the progression and metastasis of colorectal cancer. The review begins by assessing the gut microbiome’s influence on CRC development, emphasizing its association with gut-associated lymphoid tissue (GALT). The role of the Wnt signaling pathway in CRC tumor stroma is scrutinized, elucidating its impact on disease progression. Tumor budding, its effect on tumor stroma, and the implications for patient prognosis are investigated. The review also identifies conserved oncogenic signatures (COS) within CRC stroma and explores their potential as therapeutic targets. Lastly, the seed and soil hypothesis is employed to contextualize metastasis, accentuating the significance of both tumor cells and the surrounding stroma in metastatic propensity. This review highlights the intricate interdependence between CRC cells and their microenvironment, providing valuable insights into prospective therapeutic approaches targeting tumor–stroma interactions.

1 January 2024 in CLINICAL AND EXPERIMENTAL MORPHOLOGY
Verified
Journal Article
Closed access
NSNikolay K Shakhpazyan
Nikolay K Shakhpazyan
LMLiudmila Mikhaleva
Liudmila Mikhaleva
ABArkady Bedzhanyan
Arkady Bedzhanyan
ZGZarina Gioeva
Zarina Gioeva
AMA.I. Mikhalev
A.I. Mikhalev
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
Introduction. Colorectal cancer (CRC) is one of the most common oncological diseases, the pathogenesis of which is closely associated with the development of inflammation. The study of inflammation regulation, including the balance of pro- and antiinflammatory cytokines, is a promising topic for research, allowing for a deeper understanding of the pathogenesis of CRC and improving clinical approaches to the treatment for and diagnosis of this disease. This study investigates the altered secretion of proinflammatory cytokines, i.e., TNF-α and IL-1β, in CRC patients, aiming to elucidate immune dysregulation mechanisms. We sought to investigate the secretion characteristics of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), in patients with CRC. Materials and methods. We enrolled 25 newly diagnosed CRC patients and 20 age- and sex-matched controls. Monocytes were isolated from the peripheral blood of participants using magnetic separation based on the CD14 marker. The isolated monocytes were cultured and subjected to dual stimulation with bacterial lipopolysaccharide at 24 hours and 7 days, followed by quantitative measurement of basal and stimulated cytokine levels using an enzyme-linked immunosorbent assay (ELISA). Results. We revealed a significant reduction in TNF-α secretion in CRC monocytes after initial LPS stimulation, with no subsequent recovery upon restimulation. In contrast, IL-1β secretion elevated markedly in CRC patients, particularly after restimulation. These results suggest an impaired TNF-α response and an exacerbated IL-1β response in CRC, indicating a potential immune tolerance mechanism that may contribute to tumor progression. The distinct cytokine dynamics observed point at complex immune dysregulation within the CRC microenvironment. Conclusion. The observed cytokine secretion patterns may indicate immune dysregulation in the microenvironment of CRC. Our study underscores the importance of understanding the specific roles of cytokines in CRC pathogenesis and highlights the potential for targeted therapeutic interventions to modulate these immune responses. Further research is necessary to explore the underlying signaling pathways and the broader implications of these findings for CRC treatment strategies. This work provides critical insights into the pro-inflammatory cytokine profiles in CRC, advancing our understanding of the immune landscape in cancer and opening new avenues for therapeutic exploration. Keywords: colorectal cancer, cytokines, tumor necrosis factor-alpha, interleukin-1 beta, immune tolerance

1 April 2026 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
NSNikolay K Shakhpazyan
Nikolay K Shakhpazyan
LMLiudmila Mikhaleva
Liudmila Mikhaleva
ABArkady Bedzhanyan
Arkady Bedzhanyan
ZGZarina Gioeva
Zarina Gioeva
AMAlexander Mikhalev
Alexander Mikhalev
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
This review offers an in-depth analysis of mitochondrial DNA (mtDNA) mutations in colorectal cancer stem cells (CSCs), emphasizing their significant impact on tumor dynamics and potential therapeutic strategies. CSCs are a special subpopulation due to their unique capabilities for self-renewal, differentiation, and resistance to conventional therapies. Given that CSCs significantly differ from other tumor cell subpopulations, particularly in their metabolic properties, and considering that colorectal cancer is a malignancy characterized by mitochondrial dysfunction, this review aims to put together existing data on the differences in the mitochondrial genome of CSCs compared to other colorectal tumor cell subpopulations. Additionally, the review seeks to explore the potential roles of these differences and to identify new ideas for therapeutic strategies. Key topics include the identification and properties of CSCs in colorectal cancer, the distinctive features of the mitochondrial genome, and the functional consequences of mtDNA mutations. The review hypothesizes that CSCs rely on well-functioning mitochondria for crucial aspects like energy production; yet, mtDNA mutations can lead to mitochondrial dysfunction, altering CSC characteristics and influencing cancer progression. The article discusses emerging therapeutic approaches targeting mitochondrial function in colorectal CSCs and highlights the need for advanced research, including the development of preclinical models and exploration of targeted therapies, to improve the understanding and treatment of colorectal cancer.

27 September 2025 in Cells
Verified
Journal Article
Open access
PDF file
NSNikolay K Shakhpazyan
Nikolay K Shakhpazyan
LMLiudmila Mikhaleva
Liudmila Mikhaleva
НСНиколай Садыхов
Николай Садыхов
KMKonstantin Midiber
Konstantin Midiber
ABAnton S. Buchaka
Anton S. Buchaka
ABArkady Bedzhanyan
Arkady Bedzhanyan
Background: Tumor-associated microbiota are implicated in colorectal cancer (CRC). Formalin-fixed paraffin-embedded (FFPE) tumor tissue is widely available yet seldom profiled for microbiota. We tested whether quantitative and presence/absence signals of selected taxa in FFPE tumors associate with clinicopathological features. Methods: DNA from FFPE primary CRCs (n = 52) was assayed by a targeted PCR panel quantifying 30 bacterial taxa, Candida spp., and total bacterial load. Presence/absence combinations were selected by the Apriori algorithm with Fisher’s exact testing and 10,000-permutation empirical p-values. Quantitative features were modeled by LASSO logistic regression; discrimination of single taxa and combinations was evaluated by ROC/AUC. Results: In relative-abundance analyses, Fusobacterium nucleatum showed pro-metastatic value (AUC = 0.622). The best absolute-abundance model for metastasis combined F. nucleatum, Faecalibacterium prausnitzii, total bacterial load, and Akkermansia muciniphila (AUC = 0.739). Anti-metastatic directionality in relative-abundance models was driven by Acinetobacter spp.; the two-taxon set Eubacterium rectale + Acinetobacter spp. achieved AUC = 0.747. Conclusions: PCR-based profiling of FFPE CRC tumors is feasible and reveals hypothesis-generating patterns. Signals linking F. nucleatum to metastatic CRC and Acinetobacter spp. to non-metastatic disease merit validation in larger cohorts; tumor-tissue microbiome features may complement clinicopathological assessment.

5 June 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
NSNikolay K Shakhpazyan
Nikolay K Shakhpazyan
LMLiudmila Mikhaleva
Liudmila Mikhaleva
ABArkady Bedzhanyan
Arkady Bedzhanyan
ZGZarina Gioeva
Zarina Gioeva
НСНиколай Садыхов
Николай Садыхов
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
This review systematically examines the multifaceted relationship between the tumor microenvironment, stromal interactions, and colorectal cancer (CRC) progression and metastasis. The analysis begins by assessing the gut microbiome's influence on CRC development, emphasizing its association with gut-associated lymphoid tissue (GALT). The role of the Wnt signaling pathway in CRC tumor stroma is scrutinized, elucidating its impact on disease progression. Tumor budding, its effect on tumor stroma, and implications for patient prognosis are investigated. The review also identifies conserved oncogenic signatures (COS) within CRC stroma and explores their potential as therapeutic targets. Lastly, the seed and soil hypothesis is employed to contextualize metastasis, accentuating the significance of both tumor cells and the surrounding stroma in metastatic propensity. In summary, this review highlights the intricate interdependence between CRC cells and their microenvironment, providing valuable insights into prospective therapeutic approaches targeting tumor-stroma interactions.